Dr. David E. Barnes, Plaintiff-Appellant/cross-Appellee v. The Kerr Corporation, Defendant-Appellee/cross-Appellant

418 F.3d 583, 2005 U.S. App. LEXIS 16793, 2005 WL 1903829
CourtCourt of Appeals for the Sixth Circuit
DecidedAugust 11, 2005
Docket04-5546, 04-5663
StatusPublished
Cited by31 cases

This text of 418 F.3d 583 (Dr. David E. Barnes, Plaintiff-Appellant/cross-Appellee v. The Kerr Corporation, Defendant-Appellee/cross-Appellant) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dr. David E. Barnes, Plaintiff-Appellant/cross-Appellee v. The Kerr Corporation, Defendant-Appellee/cross-Appellant, 418 F.3d 583, 2005 U.S. App. LEXIS 16793, 2005 WL 1903829 (6th Cir. 2005).

Opinion

OPINION

GILMAN, Circuit Judge.

This is a products liability case brought by David E. Barnes, a practicing dentist, against the Kerr Corporation, a provider of dental amalgams (commonly known as “silver fillings”) that contain mercury, copper, tin, and silver. Barnes claims that, during a 13-year period ending in June or July of 1999, he and his staff were exposed to toxic mercury vapors when removing old fillings and inserting new ones, and that Kerr’s amalgams are the major source of his alleged mercury poisoning.

In July of 1999, Barnes brought an action against Kerr for negligence, the manufacture and sale of a defectively designed product, the failure to warn, intentional concealment, the failure to disclose a known defective condition, and breach of implied warranty. This action, which was initially brought in a Tennessee trial court, was removed to federal court by Kerr on the basis of diversity of citizenship. Despite holding that the expert testimony offered by Barnes was admissible, the district court granted summary judgment to Kerr, concluding that Barnes had not established that Kerr was responsible for the vast majority of his exposure to mercury and that, in any event, the numerous warnings provided by Kerr were adequate as a matter of law. For the reasons set forth below, we AFFIRM the judgment of the district court.

I. BACKGROUND

A. Factual background

1. Barnes’s use of dental amalgams manufactured by Kerr

Barnes began using amalgams in dental school, which he attended from 1982 until 1986. From 1986 until 1989, he was a practicing dentist in the United States Navy and, from 1989 on, he practiced dentistry in Shelbyville, Tennessee. Starting in 1986, when Kerr began manufacturing amalgams, until “June or July of 1999,” when Barnes stopped placing amalgam fillings, he claims that he purchased all of his amalgams from Kerr. Barnes resumed using dental amalgams in 2000 “[bjecause [he] could not continue to practice effectively without placing amalgam fillings,” but he used amalgams from a different company.

During the time that Kerr provided the amalgams, Barnes claims that he “used about 3,000 amalgam capsules per year from Kerr.” Approximately 700 times per year, Barnes replaced old amalgams, a procedure that entails removing the old filling and inserting a new one. Barnes also placed around 360 crowns per year, a procedure that generally involves the removal of old amalgam fillings. The amalgams produced by Kerr consist of capsules *586 of mercury and metal alloy, which the dentist combines by breaking a thin plastic wall separating the components, and then uses the amalgam as a filling.

As noted by the district court, there are approximately “35 manufacturers of dental mercury, amalgam alloy, and encapsulated dental mercury.” But Barnes presented evidence that Kerr’s products comprised 46% of the amalgam alloy market in 2003.

2. Warnings included with the dental amalgams

Barnes claims that he never received any information from Kerr stating that mixing dental amalgam presents a health risk. The jars in which the capsules were sent, however, bore prominent warning labels. These labels stated, in capital letters, that the product “CONTAIN[ED] METALLIC MERCURY” and featured an image of a skull and crossbones next to the word “POISON.” On a chart of different hazards, including flammability, reactivity, and health hazards, the labels warned that metallic mercury presents a “serious” health hazard. The labels also recommend using protective gear such as glasses, gloves, and a facemask when handling the amalgams, and warned that the ingestion of mercury could cause “Neuro-toxic/Nephrotoxic effects,” that the inhalation of mercury could cause “Bronchiolitis, Pneumonitis, [and] Pulmonary Edema,” and that even skin contact with mercury could have harmful effects, including “redness and irritation to [the] eyes and skin.”

Furthermore, each jar included an insert with directions and an additional detailed warning. After instructions about how to use the product, the word “WARNING” appears in bold, capital letters, followed by the following paragraph about the dangers of, and appropriate precautions against, mercury exposure:

Alloy amalgam capsule products contain mercury. Since mercury is a potentially hazardous substance, proper care should be taken to prevent exposure to mercury. These preventative measures include the wearing of gloves, good ventilation, the use of an enclosed amalga-mator, proper disposal of capsules once they have been activated and used, and the use of HGX or similar-type mercury absorbing chemicals in the event of spillage. Infrequently capsules may leak mercury and, as a consequence, the above precautionary measures should always be utilized.

(Emphasis in original.)

A third warning was included in the Material Safety Data Sheet (MSDS), a regularly updated document that Barnes acknowledged having received from Kerr for as long as he was purchasing Kerr products. The MSDS for the dental amalgam capsules described mercury as a “hazardous ingredient[ ]” and stated that chronic mercury poisoning could cause “nervous irritability, weakness, tremors, gingivitis, erethism and greying of the lens of the eye.” (Erethism, derived from a Greek verb meaning to irritate, is defined by the American Heritage Dictionary as the “[a]bnormal irritability or sensitivity of an organ or a body part to stimulation.” American Heritage Dictionary of the English Language, available at http://www. bartle-by.com/61/61/E0196100Mml.) The MSDS also echoed the label’s warning that mercury could have “[n]ephrotoxie effects,” stating that mercury could “aggravate[ ][k]idney disorders.”

3. Barnes’s alleged exposure to mercury

Barnes alleged in his First Amended Complaint that he was “severely injured and afflicted” from exposure to mercury, *587 and that he believed that he would be “prevented from attending to his occupational duties in the future as a direct and proximate result of these injuries and because of the need to prevent future exposures to mercury, which could result in further and additional physical and mental injuries.” This exposure allegedly came from three main sources. The primary source was “mercury vapor and mercury contained in amalgam particulate inhaled when removing existing amalgam from the teeth of patients.” According to Dr. Mark Richardson, Barnes’s expert witness, between 81% and 89.3% of Barnes’s daily exposure to mercury came from this source. Kerr, however, disputes whether the majority of amalgams that Barnes has removed during his career have been Kerr amalgams.

A second alleged source of exposure was “contaminated office air due to a variety of sources, including mercury released during trituration of capsules, opening of triturat-ed capsules, free mercury that may have leaked during transport, and particulate released into the office air during amalgam removal.” Richardson estimated that between 2.5% and 10.9% of Barnes’s daily exposure came from this source. As noted by the district court, Kerr argues that much of this exposure could have come from sources other than leaking capsules.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Greene v. LEDVANCE LLC (TV3)
E.D. Tennessee, 2024
Reynolds v. AbbVie Inc.
N.D. Illinois, 2023
Carolyn Coffman v. Armstrong International, Inc.
Court of Appeals of Tennessee, 2019
Air & Liquid Systems Corp. v. DeVries
586 U.S. 446 (Supreme Court, 2019)
Rita McDaniel v. Upsher-Smith Laboratories, Inc.
893 F.3d 941 (Sixth Circuit, 2018)
Moore v. C.R. Bard, Inc.
217 F. Supp. 3d 990 (E.D. Tennessee, 2016)
King Bradley, Jr. v. Ameristep, Inc.
800 F.3d 205 (Sixth Circuit, 2015)
Yanise Germain v. Teva Pharmaceuticals, USA, Inc
756 F.3d 917 (Sixth Circuit, 2014)
Payne v. Novartis Pharmaceuticals Corp.
967 F. Supp. 2d 1223 (E.D. Tennessee, 2013)
DiBartolo v. Abbott Laboratories
914 F. Supp. 2d 601 (S.D. New York, 2012)
Strayhorn v. Wyeth Pharmaceuticals, Inc.
882 F. Supp. 2d 1020 (W.D. Tennessee, 2012)
Esposito v. Eli Lilly & Co.
856 F. Supp. 2d 904 (E.D. Kentucky, 2012)
Bud Lee v. Metropolitan Gov't of Nashville
432 F. App'x 435 (Sixth Circuit, 2011)
Smith v. PFIZER INC.
688 F. Supp. 2d 735 (M.D. Tennessee, 2010)
Lee v. Metropolitan Government of Nashville
596 F. Supp. 2d 1101 (M.D. Tennessee, 2009)
Goldman v. Healthcare Management Systems, Inc.
559 F. Supp. 2d 853 (W.D. Michigan, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
418 F.3d 583, 2005 U.S. App. LEXIS 16793, 2005 WL 1903829, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dr-david-e-barnes-plaintiff-appellantcross-appellee-v-the-kerr-ca6-2005.